| scholarly article | Q13442814 |
| P2093 | author name string | Hongmei Zhu | |
| Xiaoping Zhang | |||
| Dong Liu | |||
| Na Zhou | |||
| Yanxia Jiang | |||
| Xiaochun Zhang | |||
| Xiaonan Yang | |||
| Guifang Lu | |||
| Chuantao Zhang | |||
| Helei Hou | |||
| Zhaoyang Qian | |||
| Zhuokun Li | |||
| P2860 | cites work | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 |
| Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers | Q26781362 | ||
| Next-generation sequencing to guide cancer therapy | Q26801946 | ||
| Management of colorectal cancer | Q26823550 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo | Q27852093 | ||
| The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis | Q27852988 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 | ||
| Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia | Q34052520 | ||
| CONTRA: copy number analysis for targeted resequencing | Q34219588 | ||
| Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing | Q34735416 | ||
| Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers | Q35772123 | ||
| Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. | Q36201032 | ||
| Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR. | Q36472281 | ||
| PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | Q36611365 | ||
| The genomic landscape of response to EGFR blockade in colorectal cancer. | Q36930106 | ||
| Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). | Q37109905 | ||
| Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing | Q37698190 | ||
| Multigene assays in metastatic colorectal cancer | Q38155485 | ||
| Treatment of NRAS-mutant melanoma. | Q38386344 | ||
| Genetic mutations in human rectal cancers detected by targeted sequencing | Q38989186 | ||
| Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer | Q39018250 | ||
| On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients | Q41102898 | ||
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. | Q46034442 | ||
| Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing | Q47163678 | ||
| Ion Torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. | Q48255185 | ||
| K-ras mutations and cetuximab in colorectal cancer | Q94852396 | ||
| P433 | issue | 62 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 105072-105080 | |
| P577 | publication date | 2017-09-27 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine | |
| P478 | volume | 8 |
| Q92648935 | Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC | cites work | P2860 |
Search more.